搜索
产品
社区
市场
新闻
经纪商
更多
CN
开始
Missed Approval But Q2 Looks Promsing
做多
United Therapeutics Corporation
(
NASDAQ:UTHR
)
DiastoAle
NASDAQ:UTHR
United Therapeutics Corporation
Trend Analysis
0
0
trendanalysis
More things down the pipeline to come, and this company is making tons of money. This price is going to fill the gap for sure and stay above 200 in Q2.
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在
使用条款
阅读更多信息。